![]() |
|
|
Department of Anesthesiology and Molecular Biology Institute, University of California, Los Angeles School of Medicine, Los Angeles, California 90095
| |
Summary |
|---|
|
|
|---|
Palmitoylation of the V2 vasopressin receptor (V2R) and its functional role were investigated in transfected cells. Palmitoylation was assessed by incubating transfected cells with [3H]palmitic acid and immunoprecipitating the receptor with an antibody raised against a portion of the third intracellular loop of V2R. Wild-type and nonglycosylated V2R yielded tritium signals at 45-55 and 40 kDa, respectively, demonstrating that the V2R is palmitoylated and that receptor palmitoylation is independent of glycosylation. Substitution of CC341/342 for serines eliminated receptor palmitoylation, whereas replacement of a single amino acid, C341S or C342S, restored partial palmitoylation. Saturation binding assays revealed decreased cell surface expression of the nonpalmitoylated receptor compared with the wild-type; this effect was more pronounced when a truncated form of V2R (G345ter) was studied. The presence of either cysteine residue (C341S or C342S) elevated receptor expression to normal levels, most likely due to the partial restoration of palmitoylation. Ligand binding affinity, hormone-induced stimulation of adenylyl cyclase activity, receptor internalization, and desensitization were not affected by the absence of palmitoylation. No increase but rather a slight decrease in the extent of receptor palmitoylation was detected after exposure to vasopressin. It was concluded that the V2R is palmitoylated in both cysteines, each cysteine is palmitoylated independently from the other, and palmitoylation enhances cell surface expression of the V2R.
| |
Introduction |
|---|
|
|
|---|
Palmitoylation is a
post-translational modification of proteins that contributes to their
localization on the plasma membrane, as exemplified by p21ras and some
of the
subunits of heterotrimeric G proteins (1, 2). The acylated
amino acid is in most cases a cysteine that is linked to palmitate by a
thioester. In the case of proteins that are intrinsic to the plasma
membrane, the acylation is suggested to occur after they transverse the
endoplasmic reticulum. This process may occur before and during the
protein entry into the Golgi apparatus and/or in the cell membrane (1, 3). After the original report by Ovchinnikov et al. (4) describing the palmitoylation of bovine rhodopsine on two cysteines downstream of the seventh transmembrane region, comparison of the amino
acid sequences of G protein-coupled receptors revealed the existence of
cysteines in a similar location in many receptor proteins. Previously,
only few G protein-coupled receptors have been shown to be
palmitoylated (for a review, see Ref. 5). These studies demonstrated
the incorporation of [3H]palmitic acid into wild-type
receptors and the loss of incorporation after mutagenesis of the
acceptor cysteine residues. A consensus sequence to identify the
acceptor site has been proposed, but the sequence of the V2R deviates
from it. Therefore, it was of interest to examine whether the V2R was
palmitoylated and in the process test the validity of the consensus
signal.
It is unclear what role palmitoylation plays in the structure/function
of G protein-coupled receptors. Ovchinnikov et al. (4)
hypothesized that the palmitoyl group anchors the carboxyl terminal
segment of the receptor to the plasma membrane, creating a fourth
intracellular loop. Anchoring to the plasma membrane may play a role in
determining the conformation of the intracellular loops involved in
receptor/G protein coupling as well as in internalization and
desensitization. For the
2-adrenoceptor, absence of
palmitoylation increases the phosphorylation of the unliganded receptor
by protein kinase A and reduces the ligand-induced increase in
phosphorylation and the coupling to the G protein Gs (6,
7). On the contrary, lack of palmitoylation of the
2-adrenoceptors and the LH/hCG did not alter G protein
coupling (8, 9). On the other hand, involvement of the palmitoyl group
in receptor internalization has been shown for
2-adrenoceptors,
2-adrenoceptors, and
LH/hCG receptors (8, 9). Hence, more data are required to generalize the role of palmitoylation in the function of G protein-coupled receptors.
The V2R is a member of the superfamily of G protein-coupled receptors that couples to the stimulatory G protein, Gs, and is located mainly in the kidney collecting ducts, in which it plays an important role in water homeostasis. In the current study, we investigated the palmitoylation of the V2R and its possible functional role. Our results demonstrate that the V2R is indeed palmitoylated and that palmitoylation enhances the level of receptor expression at the plasma membrane but otherwise is not required for the receptor to be fully active.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
DMEM, HBSS, D-PBS,
penicillin/streptomycin, 0.5% trypsin/5 mM EDTA, and FBS
were from GIBCO (Grand Island, NY). Methionine/cysteine-free DMEM was
from ICN Bichemicals (Costa Mesa, CA). Cell culture plasticware was
from COSTAR (Cambridge, MA). AVP, (
)-isoproterenol, and
3-isobutyl-1-methylxanthine were from Sigma (St. Louis, MO). Forskolin
was from Calbiochem (San Diego, CA). [3H]AVP (specific
activity, 60-80 Ci/mmol), EXPRE35S
(35S-Express Protein labeling Mix; specific activity,
>1000 Ci/mmol), [3H]palmitic acid (specific activity,
30-60 Ci/mmol), and [
-32P]ATP (specific activity,
3000 Ci/mmol) were purchased from DuPont-New England Nuclear (Boston,
MA). [3H]cAMP was from ICN Biochemicals (Irvine, CA).
Amplify was from Amersham (Arlington Heights, IL). All other reagents
were from Sigma.
Construction of mutant V2Rs. The N22Q, CC341/342SS, CC341/342GG, C341S, C342S, G345ter, and G345ter (CC341/342SS) mutations were introduced into the human V2R cDNA using a polymerase chain reaction-based approach (10). In the last two constructs, a stop codon was introduced at amino acid 345. The resulting constructs were sequenced fully according to the dideoxy chain termination method of Sanger et al. (11). For expression in eucaryotic cells, the cDNA-bearing mutants were cloned into the expression vector pcDNA3 (InVitrogen, San Diego, CA).
Cell culture and transient expression of V2R. COS.M6 or HEK 293 cells were grown in DMEM-high glucose and supplemented with 10% heat-inactivated FBS, penicillin (50 units/ml), and streptomycin (50 µg/ml). For transient transfection, COS.M6 cells, kept at <75% confluence, were plated at a density of 0.5 × 106 cells/100-mm dish and transfected the following day according to a modification of the method of Luthman and Magnusson (12). Briefly, after rinsing with HBSS, each plate with cells received 800 µl of HBSS, pH 7.05, containing 3 µg of plasmid DNA mixed with 0.5 mg/ml DEAE-Dextran. After 20 min at room temperature, 100 µM chloroquine in DMEM containing 2% FBS was added. After 3 hr at 37°, the cells were exposed to 10% DMSO in HBSS for 2 min, rinsed twice with DMEM-high glucose without additives, and returned to growth medium at 37°.
Labeling with [3H]palmitic acid and
immunoprecipitation.
[3H]Palmitic acid incorporation
was performed as described by Kennedy and Limbird (8). At 48 hr after
transfection, 1 mCi [3H]palmitic acid in 1.0 ml of 10%
FBS DMEM plus 1% DMSO was added to each 100-mm dish of transfected COS
cells (two dishes were used for each experimental point). The
[3H]palmitic acid was dried under N2 before
sequential dissolution in DMSO and DMEM. After 30 min at 37° in 5%
CO2, 2 ml of 10% FBS DMEM containing 1% DMSO was added to
each dish, and the incubation was continued at 37° for a total of 2 or 8 hr. Cells were then rinsed, washed twice with ice-cold
D-PBS, scraped from the plate, and collected by
centrifugation in D-PBS. The cell pellet from each plate
was disrupted in 500 µl of RIPA buffer (150 mM NaCl, 50 mM Tris·HCl, pH 8.0, 5 mM EDTA, 1% Nonidet
P-40, 0.5% deoxycholic acid, 0.1% SDS containing protease inhibitors
0.1 mM phenylmethylsulfonyl fluoride, 1 µg/ml soybean
trypsin inhibitor, and 0.5 µg/ml leupeptin). Homogenization was
achieved by drawing the cells through needles of decreasing gauge (20 gauge, 25 gauge) fit into a 3-ml plastic syringe. Cell extracts were
then clarified by mixing them with 50 µl of a 50% slurry of
prewashed Protein A/Sepharose in the same buffer. Prewashed Protein
A/Sepharose was prepared by the addition of 1.0 ml of 25 mg/ml BSA in
RIPA buffer, mixing for 1 hr, and by two washes with RIPA buffer alone.
For immunoprecipitation, an antibody raised against a portion of third
intracellular loop of human V2R (AntiV2 #2, peptide VPGPSERPGGRRRGR)
was added to the clarified extracts at a concentration of 10 µg/ml
and incubated overnight at 4°. The antigen/antibody complexes were
then separated by incubating the mixture with prewashed Protein
A/Sepharose for 2 hr at the same temperature. The beads were
centrifuged, washed three times for 4 min on ice with RIPA buffer, and
mixed with 80 µl of 100 µM peptide #2 in RIPA buffer
for 30 min at room temperature to elute the receptor. Where indicated,
40 µl of the eluates was mixed with 100 munits of PNGase F and
incubated at room temperature for 1 hr. After mixing with an equal
volume of 2× Laemmli sample buffer containing 50 mM
-mercaptoethanol, the samples were electrophoresed in 10%
SDS-polyacrylamide gels. Radioactive bands were visualized by treating
the gel with Amplify and exposing the dried gels to Kodak X-Omat film
at
70° for the indicated times.
Metabolic labeling with 35S-methionine/cysteine. Proteins were labeled in 100-mm dishes according to a modification of the method of Keefer and Limbird (13). At 48 hr after transfection, COS cells were fasted for 1 hr in methionine/cysteine-free DMEM and then were labeled for 1 hr 40 min or 8 hr with 2 ml of the same medium containing 100 µCi of 35S-Express Protein Labeling Mix/plate. Cells were then rinsed, and the receptor proteins were extracted and immunoprecipitated as described above. The receptor protein was analyzed by SDS-PAGE and fluorography. The effect of AVP on the intensity of the labeled receptor band was tested by labeling the cells for 1 hr 40 min as described above and adding the hormone to the medium to a final concentration of 100 nM. Twenty minutes later, the reaction was stopped by chilling the cells, followed by receptor extraction and immunoprecipitation.
Phosphorylation of the V2R in intact cells. Transiently transfected COS cells were plated onto six-well plates at a density of 1.5 × 105 cells/well at 24 hr after transfection. After 18 hr, the cells were washed and incubated for 30 min with phosphate-free MEM, followed by the addition of 100 µCi/well of [32P]H3PO4. After 2 hr at 37°, the cells were exposed to 100 nM vasopressin for 15 min at 37° and then chilled on ice and washed twice with PBS. The receptor proteins were extracted and immunoprecipitated as described above and analyzed by SDS-PAGE and autoradiography. The RIPA buffer used for the extraction contained, in addition to the protease inhibitors, 10 mM Na pyrophosphate, 10 mM NaF, and 300 nM okadaic acid as phosphatase inhibitors.
[3H]AVP binding to intact cells. Twenty four hours after transfection, cells were plated onto 24-well plates at a density of 0.5-1.0 × 105 cells/well. Binding assays were performed the following day. Cells were washed twice with ice-cold D-PBS, after which each well received 0.5 ml of ice-cold D-PBS with 2% BSA and the appropriate dilutions of [3H]AVP in the presence (nonspecific) or absence (total) of 10 µM AVP (10). Plates were incubated for 2 hr on ice in the cold room before removal of the binding mixture by aspiration. After two quick rinses with ice-cold D-PBS, 0.5 ml of 0.1 N NaOH was added to each well to extract radioactivity. After 30 min at 37°, the fluid from the wells was transferred to scintillation vials containing 3.5 ml of ULTIMA-FLO M (Packard, Meriden, CT) scintillation fluid for radioassay. Experiments were repeated at least three times. The data in the text are expressed as mean ± standard error.
Receptor-mediated internalization of [3H]AVP. COS cells were plated 24 hr after transfection at a density of 0.5-1.0 × 106 cells/plate onto 12-well plates. The next day, after two washes with D-PBS, we added to the wells 20 nM [3H]AVP in 0.5 ml of D-PBS containing 2% BSA. Cells were incubated at 37° for 20 min and chilled by placing the plates on ice. For measurement of total number of sites expressed per cell, the wells were washed with D-PBS and lysed in 0.5 ml of 0.1 N NaOH. For determination of the number of internalized receptors, the wells were treated for 5 min with a solution of 50 mM sodium citrate, 90 mM NaCl, and 0.1 mM Na2HPO4, pH 5.0 (acid wash), followed by two washes with ice-cold D-PBS. Radioactivity was extracted with 0.5 ml of 0.1 N NaOH as described above. Experiments were repeated five times. The data are expressed as mean ± standard error.
Receptor desensitization. HEK 293 cells were plated 24 hr after transfection at a density of 3.0 × 106 cells/polylysine-treated 60-mm dish. The next day, after two washes with D-PBS at room temperature, the dishes received vehicle or 100 nM AVP in 2 ml of DMEM containing 10% FBS. Cells were incubated at 37° for 5 or 20 min and chilled by placing the dishes on ice. After two washes with ice-cold D-PBS, cells were exposed twice for 30 sec to 5 mM acetic acid/150 mM NaCl followed by three washes with ice-cold D-PBS. Cells were harvested and homogenates were prepared as previously described (10). Receptor stimulation of adenylyl cyclase activity was assessed by dose-response curves to AVP.
Adenylyl cyclase activity in cell homogenates.
Adenylyl
cyclase activity was assayed as previously described (10). In a final
volume of 50 µl, the medium contained 0.1 mM
[
-32P]ATP (1-5 × 106 cpm), 4 mM MgCl2, 10 µM GTP, 1 mM EDTA, 1 mM [3H]cAMP (~10,000
cpm), 2 mM 3-isobutyl-1-methylxanthine, and a nucleoside
triphosphate regenerating system composed of 20 mM creatine
phosphate, 0.2 mg/ml (2000 units/mg) creatine phosphokinase, 0.02 mg/ml
myokinase (448 units/mg), and 25 mM Tris·HCl, pH 7.4. Hormones (diluted in 1% BSA) were present at the concentrations indicated on the figures. Reactions were stopped by the addition of 100 µl of a solution containing 40 mM ATP, 10 mM
cAMP, and 1% SDS. The cAMP formed was isolated by a modification of
the standard double chromatography over Dowex-50 and alumina columns (14, 15). Under these assay conditions, cAMP accumulations were linear
with time of incubation for
40 min and proportional to the amount of
homogenate. The activities were expressed as pmol of cAMP formed/min/mg
of homogenate protein or percent maximal Iso or VIP response. Protein
concentration was determined according to the method of Lowry (16)
using BSA as standard. Experiments were repeated at least twice. The
EC50 values are the average of the values obtained.
| |
Results |
|---|
|
|
|---|
Palmitoylation of V2R. The presence of cysteines within 15 amino acids after the seventh transmembrane region of the V2R predicted that the receptor could be palmitoylated, but as illustrated in Fig. 1, the sequence surrounding these cysteines deviated from that proposed by Bouvier et al. (5) as the acceptor site for receptor palmitoylation. The composition of the proposed consensus sequence is FXX L/I L/I (X)nCp, where F, L, and I represent phenylalanine, leucine, and isoleucine; the range for n is 0-4; and Cp is palmitoylated cysteine. This sequence, which is derived from examination of the amino acid composition of the G protein-coupled receptors first reported as palmitoylated, is rather ambiguous. To test whether the V2R is palmitoylated, it was expressed transiently in COS.M6 cells and tested for incorporation of [3H]palmitic acid as described in Experimental Procedures. Metabolic labeling and immunoprecipitation of the V2R expressed in COS.M6 cells had been previously investigated in our laboratory (17). Expression of the glycosylated wild-type V2R produced two predominant bands of immature receptor and a weaker broad band of mature V2R. The intensity of these bands varied between experiments, but they were always present. Sensitivity to endoglycosidase treatments established that the broad band at 45-55 kDa corresponded to the mature glycosylated V2R, whereas the others represented a receptor precursor that was very prone to aggregation (17). Treatment with PNGase F resulted in the appearance of a 38-40 kDa band at the expense of the broad 45-55 kDa band. The different migration of the precursor and the mature proteins was not due only to a difference in the carbohydrate component because expression of the cDNA encoding the nonglycosylated mutant form of the receptor (N22Q) produced a sharp band at 38-40 kDa and an additional band that migrated faster than its glycosylated counterpart (17, 18). These data suggested that the receptor protein undergoes a refolding process to achieve its final conformation and that this "maturation" was independent of the processing of the sugar moiety.
|
-mercaptoethanol according to Magee et al. (19), who
described the resistance of the palmitoyl bond to low concentrations of
reducing agents. This concentration of
-mercaptoethanol incorporated
into the Laemmli sample buffer provided a reducing environment that
facilitated the entry and migration of the proteins in SDS-PAGE. As
illustrated in Fig. 2, whether the receptor protein was glycosylated
did not affect the incorporation of palmitic acid into the V2R. The
experiments were carried out with the glycosylated and nonglycosylated
receptor protein with identical results.
|
|
|
Ligand binding activity of nonpalmitoylated V2R. Cell surface expression and ligand binding affinity of the wild-type V2R and the receptors mutagenized at one or both acceptor cysteines were assessed by performing saturation binding assays in intact cells. The experiments were performed repeatedly with the glycosylated and nonglycosylated mutant proteins with similar results. Fig. 5 illustrates the results obtained in a representative experiment for saturation binding of the glycosylated V2R and Scatchard analysis of the data. Mutagenesis of both cysteines (CC341/342SS) reduced the number of receptors expressed in the plasma membrane. As shown in Table 1, the average receptor expression calculated from six experiments was 57 ± 3% of the wild-type V2R. On the other hand, mutation of only one of the cysteine residues, C341S or C342S, did not alter the level of expression of the receptor (Fig. 5 and Table 1).
|
|
G protein coupling of nonpalmitoylated V2R. The ability of the nonpalmitoylated receptor to interact with G proteins was assessed by measuring AVP stimulation of adenylyl cyclase activity mediated by mutant receptors expressed in COS.M6 and HEK 293 cells. As seen in Fig. 6A, the CC341/342SS mutant V2R expressed in COS.M6 cells was able to stimulate adenylyl cyclase activity to the same extent as the wild-type receptor with an EC50 value of 90 pM for both. Similar results were obtained in HEK 293T cells (Fig. 6B). Truncation of the V2R at G345 did not alter the ability of the receptor protein to mediate AVP stimulation of adenylyl cyclase activity compared with the wild-type receptor. Lack of palmitoylation in the V2R G345ter reduced the maximal stimulation of adenylyl cyclase activity to 70% of the maximum response of the palmitoylated truncated receptor and produced a right shift in the EC50 value from 0.8 nM (G345ter) to 2 nM (G345ter-CC341/342SS). The observed rightward shift is most likely due to the reduction in the abundance of receptors per cell documented in Table 1 than to altered coupling to Gs. The coupling data were examined using the glycosylated truncated form of the receptor.
|
Internalization of nonpalmitoylated V2R. The impact of the absence of palmitoylation on receptor internalization was assessed by incubating COS.M6 cells expressing wild-type or either the CC341/342SS or CC341/342GG mutant receptors with 20 nM [3H]AVP and measuring the efficiency of the different receptors to internalize the ligand. As illustrated in Fig. 7A, the results indicated that 54 ± 2%, 58 ± 1%, and 52 ± 2% (five experiments) of the receptors were internalized for the wild-type, CC341/342SS, and CC341/342GG V2R, respectively. For each experimental condition, the radioactivity remaining in the wells after the PBS wash (described in Experimental Procedures) was used as the 100% value. These results indicated that V2R internalization and G protein coupling were not affected by the lack of palmitoylation.
|
Effect of ligand on nonpalmitoylated V2R desensitization and
phosphorylation.
Ligand induced desensitization of
nonpalmitoylated receptor was examined as described in Experimental
Procedures. Cells expressing the wild-type or the mutant receptor were
exposed to 100 nM AVP, subjected to acid washes, and
homogenized. Adenylyl cyclase activity of the cell extracts was
measured in the presence of various concentrations of AVP to examine
whether receptor desensitization was changed by the absence of
palmitoylation. As illustrated in Fig. 7B, the decrease in maximal
response to AVP was the same for the mutant and the wild-type receptor
after 5- or 20-min treatment with the hormone; the shift in
EC50 value was also similar for both receptors (data not
shown). Contrary to what has been described for the
2-adrenergic receptor, there was no change on the basal
or ligand-stimulated phosphorylation of the V2R when both cysteines
were eliminated, as shown in Fig. 8.
|
2-adrenergic receptor that the
effect of agonist on palmitic acid turnover was more apparent after
shorter labeling times (22). As illustrated in Fig. 9,
exposure to the hormone slowed the migration of the V2R in SDS-PAGE,
probably due to ligand-induced phosphorylation of the receptor (21). Densitometric quantification of the tritiated palmitic acid signal revealed a 26% decrease in the amount of palmitic acid associated with
the receptor. Receptor labeled for the same time with
35S-methionine/cysteine and exposed to AVP under similar
conditions showed the expected change in migration without a
significant decrease in the intensity of the receptor band (8.3%).
These results suggest that contrary to what was reported for the
2-adrenoceptor, exposure of the V2
vasopressin receptor to ligand in the presence of labeled palmitic acid
does not result in increased turnover but rather in loss of palmitic
acid from a fraction of the receptor.
|
| |
Discussion |
|---|
|
|
|---|
Palmitoylation of V2R was investigated by immunoprecipitation of receptor proteins expressed transiently in COS.M6 cells and detection of incorporated [3H]palmitic acid. In cells expressing the wild-type glycosylated V2R, [3H]palmitic acid incorporation resulted in the appearance of a broad radioactive band at 45-55 kDa, which is the expected size for the mature receptor form. Deglycosylation with PNGase F produced a sharp band at 40 kDa. As seen in Fig. 2, this band was identical to the band obtained from cells expressing nonglycosylated receptor (17, 18). These results demonstrated that the V2R is palmitoylated and that protein glycosylation was not required to observe palmitoylation.
Analogous to other G protein-coupled receptors, the palmitoylation site
was expected to be located 10-12 amino acids downstream of the seventh
transmembrane region. Some receptors, such as the
2- and
2-adrenoceptors, contain only one palmitoylated
cysteine; others, like rhodopsin and the LH/hCG receptor, contain two
adjacent cysteine residues, both of which are palmitoylated. The two
cysteine residues of the V2R at positions 341 and 342 were the
candidate sites for palmitoylation. Mutation of these cysteines to
serines abolished the incorporation of [3H] palmitic
acid, identifying them as the palmitoylation site. Palmitoylation of
the V2R challenged the validity of the consensus sequence proposed by
Bouvier et al. (5) because the acceptor sequence for the V2R
lacks a phenylalanine at the predicted location.
Mutants containing only one cysteine (C341S or C342S) were used to examine whether one or both are palmitoylated. Incorporation of palmitic acid was detected for both mutations at a level close to 50% of the wild-type protein, demonstrating that both cysteines are palmitoylated and that each one can be palmitoylated independently of the other. This is contrary to the observation by Karnik et al. (23), who established that in bovine opsin the palmitoylation of Cys323 is dependent on the palmitoylation of Cys322. In turn, our results are in agreement with those of Kawate and Menon (9), who demonstrated independent palmitoylation of Cys621 and Cys622 of the LH/hCG receptor.
In addition to the tritium signal coincident with the mature receptor, a tritium signal was also present at a location coincidental with the migration of the immature receptor. The lack of correlation of this band with the presence of Cys341/Cys342 suggests that it is due to a protein that coprecipitates with the receptor.
Assessment of the level of expression of the wild-type and the nonpalmitoylated V2R revealed a 40-50% reduction in the number of binding sites for the latter. The dependency of this effect on palmitoylation was demonstrated by the restoration of wild-type-like levels of expression for the single-cysteine mutant V2Rs. A similar reduction of cell surface expression of the CC341/342SS mutant V2R was reported by Schulein et al. (22), but these authors did not examine the effect of single amino acid mutations at the palmitoylation sites on receptor expression. A reduction in levels of receptor expression has been reported for the nonpalmitoylated LH/hCG receptor; however, this effect was not reversed by mutagenizing a single cysteine (9). Therefore, we are the first to report a direct correlation between cell surface expression of a G protein-coupled receptor and palmitoylation. Because the reduction in receptor expression was observed when either serine or glycine replaced cysteine, this change is most likely due to the absence of palmitoylation rather than to the identity of the amino acid present. Palmitoylation may affect the processing of the newly synthesized receptors because our results showed an increase in the quantity of immature nonpalmitoylated mutant V2R compared with the amount present for the wild-type receptor. After ligand-induced sequestration of receptors expressed in HEK 293 cells, it was not possible to detect the return of receptors to the cell surface after removal of the hormone; both wild-type and nonpalmitoylated proteins behave in the same manner (data not shown). Therefore, it was not possible to test experimentally whether there are differences in receptor recycling.
Despite the differences in cell surface expression between the nonpalmitoylated V2R and the single palmitoylated or wild-type V2R, ligand binding affinity and G protein coupling of the receptor were not affected in our experiments. Schulein et al. (24) did not observe changes in ligand binding affinity but described a 2-7-fold change in the EC50 value of AVP stimulation of adenylyl cyclase activity for the mutants compared with the wild-type receptor. Because their study was performed in stably transfected cells expressing a varying number of sites per cell, they proposed receptor abundance as the cause for the observed differences, a result that is in agreement with data we previously reported (10). The transfection conditions used in our experiments result in high levels of receptor expression such that only significant reductions in abundance observed in binding assays are accompanied by detectable changes in coupling to Gs.
The lack of interference with G protein coupling observed for the
nonpalmitoylated V2R is in agreement with what has been reported for
the
2-adrenoceptor and the LH/hCG receptor (8, 9). Thus,
the data suggest that once the receptor is inserted properly into the
plasma membrane, it does not require palmitoylation to interact
successfully with Gs. In accord with these results, we
observed that the CC341/342SS was as good as the wild-type V2R as
substrate for ligand-induced receptor phosphorylation. In addition,
ligand-induced desensitization of the V2R was not affected by lack of
palmitoylation. The alteration in G protein coupling reported for the
nonpalmitoylated
2-adrenoceptors has been recently
ascribed to the modulation of phosphorylation of this protein by the
presence or absence of palmitic acid (6, 7). The V2R does not contain
such a site, and for the
2-adrenoceptor, once the
adjacent cAMP-dependent protein kinase site is eliminated, there is no
effect of palmitoylation in the coupling to Gs.
In apparent contrast with what Schulein et al. (24) reported, we did not observe a significant change in agonist-induced V2R internalization as a consequence of abolishing palmitoylation. Close examination of the reported differences in receptor internalization reported by these authors reveals that in their experiments, the internalization of the wild-type and nonpalmitoylated V2Rs occurring within the first 5 min of exposure to AVP was virtually identical, although they chose to focus their comments on the differences in the subsequent slower rate of internalization. The use of stably as opposed to transiently transfected cells could be argued as an explanation for the difference, but changes in internalization of the nonpalmitoylated LH/hCG receptor expressed in transiently transfected 293T cells have been observed (9). We have no explanation for the differences observed between these studies.
The turnover of palmitic acid attached to G protein
subunits and
some G protein-coupled receptors has been found to be modified by
occupancy of the receptor by ligand (25). The ligand-induced increases
in the amount of radioactive palmitic acid associated with the
2-adrenoceptor was interpreted as a consequence of
increased turnover of the fatty acid. Recently, Loisel et
al. (26) reported that the extent of palmitoylation of the
2-adrenoceptor lacking the adjacent protein kinase A
phosphorylation site was not altered by exposure to ligand, suggesting
a correlation between phosphorylation and palmitoylation for this
receptor. The V2R lacks acceptor sites for protein kinase A, and we
have shown that phosphorylation is not altered by lack of
palmitoylation. Therefore, it was not surprising that treatment with
100 nM AVP for 20 min during a 2-hr labeling period did not
enhance the amount of tritiated palmitic acid associated with the
receptor. As for the observed reduction of palmitic acid, it could be
partially due to ligand-induced sequestration and subsequent
degradation of the receptor, reflecting loss of protein, and partially
to enhanced depalmitoylation.
In summary, the V2R is palmitoylated at the two cysteine residues located toward the carboxyl terminus of the receptor. The two sites are palmitoylated independently of each other, and palmitoylation of these residues contributes to V2R expression in the plasma membrane. Once the receptor reaches the membrane, its function does not seem to be influenced by the presence of the fatty acids. These data suggest that receptor palmitoylation may play a role in maintaining the insertion of the V2R into the plasma membrane.
| |
Footnotes |
|---|
Received September 30, 1996; Accepted March 31, 1997
This work was supported in part by NIH Grant DK 41-244 to MB.
Send reprint requests to: Mariel Birnbaumer, Ph.D., UCLA School of Medicine, Dept. of Anesthesiology, 10833 Le Conte Avenue, Box 951778, Los Angeles, CA 90095. E-mail: marielb{at}cvmail.anes.ucla.edu
| |
Abbreviations |
|---|
LH, luteinizing hormone; hCG, human chorionic gonadotropin; DMEM, Dulbecco's modified Eagle's medium; HBSS, Hanks' balanced salt solution; D-PBS, Dulbecco's phosphate-buffered saline; FBS, fetal bovine serum; AVP, arginine vasopressin; Iso, isoproterenol; VIP, vasoactive intestinal peptide; HEK, human embryonic kidney; V2R, V2 vasopressin receptor; RIPA, radioimmunoprecipitation assay.
| |
References |
|---|
|
|
|---|
| 1. | Olson, E. N. Modification of proteins with covalent lipids. Prog. Lipid Res. 27:177-197 (1988)[Medline]. |
| 2. |
Linder, M. E.,
C. Kleuss, and
S. M. Mumby.
Palmitoylation of G-protein subunits.
Methods Enzymol.
250:315-330 (1995).
|
| 3. |
Bonatti, S,
G. Migliaccio, and
K. Simons.
Palmitoylation of viral membrane glycoproteins takes place after exit from the endoplasmic reticulum.
J. Biol. Chem.
264:12590-12595 (1989) |
| 4. | Ovchinnikov, Y. A., N. G. Abdulaev, and A. S. Bgachuk. Two adjacent cysteine residues in the C-terminal cytoplasmic fragment of bovine rhodopsin are palmitoylated. FEBS Lett. 230:1-5 (1988)[Medline]. |
| 5. | Bouvier, M., T. P. Loisel, and T. Hebert. Dynamic regulation of G-protein coupled receptor palmitoylation: potential role in receptor function. Biochem. Soc. Trans. 23:577-581 (1995)[Medline]. |
| 6. |
Moffett, S.,
L. Adam,
H. Bonin,
T. P. Loisel,
M. Bouvier, and
B. Mouillac.
Palmitoylated Cys341 modulates phosphorylation the 2-adrenergic receptor by the cAMP-dependent protein kinase.
J. Biol. Chem.
271:21490-21497 (1996) |
| 7. |
O'Dowd, B. F.,
M. Hnatowich,
M. G. Caron,
R. J. Lefkowitz, and
M. Bouvier.
Palmitoylation of the human 2-adrenergic receptor: mutation of Cys341 in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the receptor.
J. Biol. Chem.
264:7564-7569 (1989) |
| 8. |
Kennedy, M. E. and
L. E. Limbird.
Mutations of the 2A-adrenergic receptor that eliminate detectable palmitoylation do not perturb receptor-G-protein coupling.
J. Biol. Chem.
268:8003-8011 (1993) |
| 9. |
Kawate, N. and
K. M. J. Menon.
Palmitoylation of luteinizing hormone/human choriogonadotropin receptors in transfected cells: abolition of palmitoylation by mutation of Cys-621 and Cys-622 residues in the cytoplasmic tail increases ligand-induced internalization of the receptor.
J. Biol. Chem.
269:30651-3065 (1994) |
| 10. | Birnbaumer, M. S., S. Gilbert, and W. Rosenthal. An extracellular CNDI mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand and coupling to Gs/adenylyl cyclase system. Mol. Endocrinol. 8:886-894 (1994)[Abstract]. |
| 11. |
Sanger, F.,
S. Nicklen, and
A. B. Coulson.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467 (1977) |
| 12. |
Luthman, H. and
G. Magnusson.
High efficiency polyoma DNA transfection of chloroquine-treated cells.
Nucleic Acids Res.
11:1295-1308 (1983) |
| 13. |
Keefer, J. R. and
L. E. Limbird.
The alpha 2A-adrenergic receptor is targeted directly to the basolateral membrane domain of Madin-Darby canine kidney cells independent of coupling to pertussis toxin GTP-binding proteins.
J. Biol. Chem.
268:11340-11347 (1993) |
| 14. |
Bockaert, J.,
M. Hunzicker-Dunn, and
L. Birnbaumer.
Hormone-stimulated desensitization of hormone-dependent adenylyl cyclase: dual action of luteinizing hormone on pig graafian follicle membranes.
J. Biol. Chem.
251:2653-2663 (1976) |
| 15. | Salomon, Y., C. Londos, and M. Rodbell. A highly sensitive adenylate cyclase assay. Anal. Biochem. 58:541-548 (1974)[Medline]. |
| 16. |
Lowry, O. H.,
N. J. Rosebrough,
O. L. Farr, and
R. J. Randall.
Protein measurement with the Folin phenol reagent.
J. Biol. Chem.
193:265-275 (1951) |
| 17. | Innamorati, G., H. Sadeghi, and M. Birnbaumer. A fully active nonglycosylated V2 vasopressin receptor. Mol. Pharmacol. 50:467-473 (1996)[Abstract]. |
| 18. | Sadeghi, H. M., G. Innamorati, and M. Birnbaumer. Maturation of receptor proteins in eukaryotic expression systems. J. Signal Transd. Rec. Res. 17:433-445 (1997). |
| 19. | Magee, A. I., J. Wootton, and J. De Bony. Detecting radiolabeled lipid-modified proteins in polyacrylamide gels. Methods Enzymol. 250:330-336 (1995)[Medline]. |
| 20. | Sadeghi, H. M., G. Innamorati, and M. Birnbaumer. An X-linked NDI mutation reveals a requirement for cell surface V2R expression. Mol. Endocrinol., in press. |
| 21. |
Innamorati, G.,
H. Sadeghi,
A. N. Eberle, and
M. Birnbaumer.
Phosphorylation of the V2 vasopressin receptor.
J. Biol. Chem.
272:2486-2492 (1997) |
| 22. |
Mouillac, B.,
M. Caron,
H. Bonin,
M. Dennis, and
M. Bouvier.
Agonist-modulated palmitoylation of 2-adrenergic receptor in Sf9 cells.
J. Biol. Chem.
267:21733-21737 (1992) |
| 23. |
Karnik, S. S.,
K. D. Ridge,
S. Bhattacharaya, and
H. G. Khorana.
Palmitoylation of bovine opsin and its cysteine mutants in COS cells.
Proc. Natl. Acad. Sci. USA
90:40-44 (1993) |
| 24. | Schulein, R., U. Liebenhoff, H. Muller, M. Birnbaumer, and W. Rosenthal. Properties of the human arginine vasopressin V2 receptor after site-directed mutagenesis of its putative palmitoylation site. Biochem. J. 313:611-616 (1996). |
| 25. | Ross, E. M. Palmitoylation in G-protein signalling pathways. Curr. Biol. 5:107-109 (1995)[Medline]. |
| 26. |
Loisel, T. P.,
L. Adam,
T. Hebert, and
M. Bouvier.
Agonist stimulation increases the turnover rate of 2AR-bound palmitate and promotes receptor depalmitoylation.
Biochemistry
35:15923-15932 (1996)[Medline].
|
This article has been cited by other articles:
![]() |
G. W. Sawyer, F. J. Ehlert, and C. A. Shults Cysteine Pairs in the Third Intracellular Loop of the Muscarinic M1 Acetylcholine Receptor Play a Role in Agonist-Induced Internalization J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 196 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Yangthara, A. Mills, V. Chatsudthipong, L. Tradtrantip, and A. S. Verkman Small-Molecule Vasopressin-2 Receptor Antagonist Identified by a G-Protein Coupled Receptor "Pathway" Screen Mol. Pharmacol., July 1, 2007; 72(1): 86 - 94. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Madziva and M. Birnbaumer A Role for ADP-ribosylation Factor 6 in the Processing of G-protein-coupled Receptors J. Biol. Chem., April 28, 2006; 281(17): 12178 - 12186. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Robben, N. V. A. M. Knoers, and P. M. T. Deen Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model Am J Physiol Renal Physiol, August 1, 2005; 289(2): F265 - F272. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ponimaskin, A. Dumuis, F. Gaven, G. Barthet, M. Heine, K. Glebov, D. W. Richter, and M. Oppermann Palmitoylation of the 5-Hydroxytryptamine4a Receptor Regulates Receptor Phosphorylation, Desensitization, and {beta}-Arrestin-Mediated Endocytosis Mol. Pharmacol., May 1, 2005; 67(5): 1434 - 1443. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Van Itallie, T. M. Gambling, J. L. Carson, and J. M. Anderson Palmitoylation of claudins is required for efficient tight-junction localization J. Cell Sci., April 1, 2005; 118(7): 1427 - 1436. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Robert, E. Clauser, P. X. Petit, and M. A. Ventura A Novel C-terminal Motif Is Necessary for the Export of the Vasopressin V1b/V3 Receptor to the Plasma Membrane J. Biol. Chem., January 21, 2005; 280(3): 2300 - 2308. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Zhou, L. Liu, M. Reddivari, and X. A. Zhang The Palmitoylation of Metastasis Suppressor KAI1/CD82 Is Important for Its Motility- and Invasiveness-Inhibitory Activity Cancer Res., October 15, 2004; 64(20): 7455 - 7463. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. Charest and M. Bouvier Palmitoylation of the V2 Vasopressin Receptor Carboxyl Tail Enhances {beta}-Arrestin Recruitment Leading to Efficient Receptor Endocytosis and ERK1/2 Activation J. Biol. Chem., October 17, 2003; 278(42): 41541 - 41551. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Thibonnier, C. L. Plesnicher, K. Berrada, and L. Berti-Mattera Role of the human V1 vasopressin receptor COOH terminus in internalization and mitogenic signal transduction Am J Physiol Endocrinol Metab, July 1, 2001; 281(1): E81 - E92. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gimpl and F. Fahrenholz The Oxytocin Receptor System: Structure, Function, and Regulation Physiol Rev, April 1, 2001; 81(2): 629 - 683. [Abstract] [Full Text] [PDF] |
||||
![]() |
|